ADVFN - Advanced Financial Network.
HOME» NASDAQ » Z » ZGEN Stock Price » ZGEN Stock News

Zymogenetics Share News

 Zymogenetics (mm) Stock Price
ZGEN Stock Price
 Zymogenetics (mm) Stock Chart
ZGEN Stock Chart
 Zymogenetics (mm) Stock News
ZGEN Stock News
 Zymogenetics (mm) Company Information
ZGEN Company Information
 Zymogenetics (mm) Stock Trades
ZGEN Stock Trades

Bristol-Myers Squibb To Buy Biotech ZymoGenetics For $836 Million

DOW JONES NEWSWIRES Bristol-Myers Squibb Co. (BMY) has agreed to pay $9.75 a share in cash for biotechnology company ZymoGenetics Inc. (ZGEN), an 84% premium from the closing price Tuesday. ZymoGenetics's shares shot up 83% to $9.70 after hours. The stock was down 17% this year as of the close. Bristol-Myers's shares closed at $26.61 and rose 7 cents after hours. That stock was up 5% this year as of the close. The $836 million deal is expected to reduce Bristol-Myers' earnings by 3 cents a share this year and 7 cents a share next year. Bristol-Myers plans to begin a cash tender offer on or about Thursday and the offer is expected to close about 30 days later. The acquisition agreement says ZymoGenetics will not solicit competing offers and Bristol-Myers will finance the acquisition from its existing cash resources. Bristol-Myers Chief Executive Lamberto Andreotti said the acquisition gives the company "full ownership of a promising investigational biologic that strengthens our very diversified Hepatitis C portfolio." The two companies have collaborated on development of pegylated-interferon lambda since January 2009. The product is now in Phase II trials. Andreotti also noted ZymoGenetics's "proven capabilities with therapeutic proteins and revenue from a marketed specialty surgical biologic." Among ZymoGenetics's products are Recothrom, a drug for use in surgery to prevent blood clotting; IL-21 protein, which is in Phase II testing as a potential immunotherapy treatment for metastatic melanoma; and six biologic drug candidates for atopic dermatitis. The company also is in six partnered programs with Merck KGaA (MKGAY, MRK.XE) affiliate EMD Serono Inc. and Novo Nordisk A/S (NVO, NOVO.B.KO). -By Kathy Shwiff, Dow Jones Newswires; 212-416-2357; Kathy.Shwiff@dowjones.com Order free Annual Report for ZymoGenetics, Inc. Visit http://djnewswires.ar.wilink.com/?link=ZGEN or call 1-888-301-0513

Stock News for Zymogenetics (ZGEN)
DateTimeHeadline
09/29/201007:03:38ZymoGenetics Reports "Positive" Results In Melanoma Study
09/08/201002:00:11Novo Nordisk Agrees To Sell ZymoGenetics Stake For DKK1.1 Billion
09/07/201018:39:13Bristol-Myers Squibb To Buy Biotech ZymoGenetics For $836 Million
12/08/200902:39:00Novo Nordisk Signs License And Patent Deal With ZymoGenetics

Zymogenetics and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad